Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A proportion of anaplastic large cell lymphomas possess the translocation t(2;5)(p23;q35) which fuses the nucleophosmin (NPM) nucleolar phosphoprotein gene on 5q35 to the anaplastic lymphoma kinase (ALK) gene on 2p23, resulting in the expression of a novel NPM-ALK fusion protein. This can be detected immunohistochemically with the the monoclonal antibody ALK1. 49 cases of anaplastic lymphoma were induced in the study on the basis of CD30-positivity and anaplastic morphology. Immunostaining was performed with the ALK1 antibody and also for a panel of other antigens (CD20, CD79a, CD43, CD3, CD45RO, Epithelial Membrane-Antigen (EMA) and EBV LMH), on routinely processed paraffin sections. 11 cases were ALK1-positive (1 T-cell, 10 null). A further 23 T/null lymphomas were ALK1-negative. 15 B-cell lymphomas were ALK1-negative. ALK1-positivity was associated with EMA positivity in 9/11 cases. The ALK1-positive cases occured in younger patients (mean age 24.5 years) than the T/null ALK1-negative cases (mean age 50.3 years) or B-cell cases (mean age 51.1 years). Extra-nodal involvement was not significantly more frequent in the ALK1-positive patients. Survival data on 45 patients showed a trend towards longer survival in the patients with the ALK1-positive tumours. The usefulness of ALK1 immunostaining in the diagnosis of anaplastic large cell lymphoma is confirmed. ALK1 positivity defines a distinctive clinicopathologic subgroup of anaplastic lymphoma characterised by T/null phenotype, young age and a relatively good prognosis.

Type

Journal article

Journal

Journal of Cellular Pathology

Publication Date

15/08/2001

Volume

5

Pages

233 - 239